JP2024527021A - 非嚢胞性線維症気管支拡張症の治療 - Google Patents

非嚢胞性線維症気管支拡張症の治療 Download PDF

Info

Publication number
JP2024527021A
JP2024527021A JP2024504780A JP2024504780A JP2024527021A JP 2024527021 A JP2024527021 A JP 2024527021A JP 2024504780 A JP2024504780 A JP 2024504780A JP 2024504780 A JP2024504780 A JP 2024504780A JP 2024527021 A JP2024527021 A JP 2024527021A
Authority
JP
Japan
Prior art keywords
cms
ncfb
cba
pulmonary
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527021A5 (https=
JPWO2023012280A5 (https=
Inventor
パオラ カステラーニ
Original Assignee
ザンボン ソシエタ ペル アチオニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザンボン ソシエタ ペル アチオニ filed Critical ザンボン ソシエタ ペル アチオニ
Publication of JP2024527021A publication Critical patent/JP2024527021A/ja
Publication of JP2024527021A5 publication Critical patent/JP2024527021A5/ja
Publication of JPWO2023012280A5 publication Critical patent/JPWO2023012280A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024504780A 2021-08-05 2022-08-04 非嚢胞性線維症気管支拡張症の治療 Pending JP2024527021A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21189819.2A EP4129322A1 (en) 2021-08-05 2021-08-05 Treatment of non-cystic fibrosis bronchiectasis
EP21189819.2 2021-08-05
PCT/EP2022/071960 WO2023012280A1 (en) 2021-08-05 2022-08-04 Treatment of non-cystic fibrosis bronchiectasis

Publications (3)

Publication Number Publication Date
JP2024527021A true JP2024527021A (ja) 2024-07-19
JP2024527021A5 JP2024527021A5 (https=) 2025-07-31
JPWO2023012280A5 JPWO2023012280A5 (https=) 2025-07-31

Family

ID=77226670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504780A Pending JP2024527021A (ja) 2021-08-05 2022-08-04 非嚢胞性線維症気管支拡張症の治療

Country Status (8)

Country Link
US (1) US20240342239A1 (https=)
EP (2) EP4129322A1 (https=)
JP (1) JP2024527021A (https=)
CN (1) CN117794559A (https=)
AU (1) AU2022324695A1 (https=)
BR (1) BR112024001945A2 (https=)
CA (1) CA3226916A1 (https=)
WO (1) WO2023012280A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2343122B (en) 1998-10-26 2003-01-08 Medic Aid Ltd Improvements in and relating to nebulisers

Also Published As

Publication number Publication date
EP4129322A1 (en) 2023-02-08
CN117794559A (zh) 2024-03-29
WO2023012280A1 (en) 2023-02-09
BR112024001945A2 (pt) 2024-04-30
US20240342239A1 (en) 2024-10-17
EP4380592A1 (en) 2024-06-12
CA3226916A1 (en) 2023-02-09
AU2022324695A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
RU2563809C2 (ru) Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза
KR101801864B1 (ko) 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
JP2008503500A (ja) 気管支感染症の治療法
Kerwin et al. Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials
Elborn et al. Bronchiectasis and inhaled tobramycin: a literature review
Bourdet et al. Key concepts
Schwarz et al. Tobramycin safety and efficacy review article
US20120237564A1 (en) Use of Aerosolized Antibiotics for Treating Chronic Obstructive Pulmonary Disease
TW201138785A (en) Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease
Amirav et al. Primary ciliary dyskinesia: prospects for new therapies, building on the experience in cystic fibrosis
JP2024527021A (ja) 非嚢胞性線維症気管支拡張症の治療
US12178841B2 (en) Treatment of non-cystic fibrosis bronchiectasis
US7973029B2 (en) Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases
EA052469B1 (ru) Лечение некистозных фиброзных (немуковисцидозных) бронхоэктазов
CN117412756A (zh) 磷霉素和粘菌素联合用于抗生物膜相关的细菌感染
Adkison et al. Management of acute exacerbations of chronic obstructive pulmonary disease
Feizabadi et al. The Potential Role of Aerosolized Colistin in the Ventilator-Associated Pneumonia Management Caused by Multidrug-Resistant Gram-Negative Bacteria: A Randomized Clinical Trial
Haworth et al. Two randomised controlled trials of inhaled liposomal ciprofloxacin (ARD-3150) in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas Aeruginosa
WO2025250560A1 (en) Methods for treating bronchiectasis
Price effect of background long-acting beta
HK1168786A (en) Use of aerosolized levofloxacin for treating cystic fibrosis
HK1168786B (en) Use of aerosolized levofloxacin for treating cystic fibrosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250723